89bio

89bio Operating Cash Flow

Delisted

The Operating Cash Flow of 89bio (ETNB) as of Nov 8, 2026 is -367.82 M USD. In the previous year, Operating Cash Flow was -129.19 M USD — a change of 184.72% (lower).

Operating Cash Flow

-367.82 MUSD

YoY

184.72%

Last updated:

Operating Cash Flow of 89bio is 2024 -367.82 M USD. Operating Cash Flow of 89bio was 2023 -129.19 M USD. It decreases by 184.72% lower compared to the previous year.

The 89bio Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-12.47 M USD
Jan 1, 2019
-25.46 M USD
Jan 1, 2020
-46.24 M USD
Jan 1, 2021
-76.78 M USD
Jan 1, 2022
-81.09 M USD
Jan 1, 2023
-129.19 M USD
Jan 1, 2024
-367.82 M USD
The 89bio Operating Cash Flow history
YEAROperating Cash FlowYoY
-367.82 MUSD+184.72%
-129.19 MUSD+59.31%
-81.09 MUSD+5.61%
-76.78 MUSD+66.03%
-46.24 MUSD+81.63%
-25.46 MUSD+104.19%
-12.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 89bio stock

Operating Cash Flow of 89bio is -367.82 M USD in 2024.

Operating Cash Flow of 89bio changed from -129.19 M USD to -367.82 M USD, representing a 184.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow 89bio since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's 89bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — 89bio

All Key Metrics — 89bio